Unique ID issued by UMIN | UMIN000017093 |
---|---|
Receipt number | R000019823 |
Scientific Title | The combination therapy of prednisolone and cyclosporine for initial onset of Vogt-Koyanagi-Harada disease. |
Date of disclosure of the study information | 2015/04/10 |
Last modified on | 2020/04/27 13:47:55 |
The combination therapy of prednisolone and cyclosporine for initial onset of Vogt-Koyanagi-Harada disease.
PSL/CYA combination therapy for VKH disease
The combination therapy of prednisolone and cyclosporine for initial onset of Vogt-Koyanagi-Harada disease.
PSL/CYA combination therapy for VKH disease
Japan |
Vogt-Koyanagi-Harada disease
Ophthalmology |
Others
NO
To investigate the efficacy of the combination therapy of prednisolone and cyclosporine for initial onset of Vogt-Koyanagi-Harada disease.
Safety,Efficacy
Exploratory
Proportion of subjects showing recurrences of uveitis with VKH disease
Interventional
Parallel
Randomized
Cluster
Open -no one is blinded
Active
2
Treatment
Medicine |
1.The group given only prednisolone
mPSL 1000mg Intravenous Infusion 3 days
PSL 0.6-0.7mg/kg Oral Administrarion 10 days
PSL 0.5-0.6mg/kg Oral Administrarion 10 days
PSL 0.4-0.5mg/kg Oral Administrarion 10 days
PSL 0.3-0.4mg/kg Oral Administrarion 4 weeks
PSL 0.2-0.3mg/kg Oral Administrarion 4 weeks
PSL 0.1-0.2mg/kg Oral Administrarion 4 weeks
PSL 0.05-0.1mg/kg Oral Administrarion 8 weeks
PSL 0.05-0.1mg/kg every other day Oral Administrarion 4 weeks
2.The group given combination of prednisolone and cyclosporine
In addition to "1.",CYA 3mg/kg is administered from day 4
20 | years-old | <= |
70 | years-old | >= |
Male and Female
1.Patients of initial onset VKH disease who present all of a) to d)
a)Within 4 weeks from disease onset
b)Showing anterior chamber cells maximum 2+
c)Without sunset glow fundus
2.Complete or incomplete type of VKH disease
3.Showing cerebrospinal fluid pleocytosis or meningeal irritation signs except headache alone
4.Who can recieve the treatment within 4 weeks from the disease onset
1.Renal dysfunction
2.Immunosuppressant treatment including steroid
3.Immunocompromised condition
4.Females who are pregnant or lactating patients or who are suspicious of pregnant
5.Malignant neoplasm
6.Ontraocular surgery (except for cataract surgery) or glaucoma surgery previously,or speculate to be required in the periods of this study
7.Investigator declare a subject ineligible for any sound reasons
120
1st name | Rie |
Middle name | |
Last name | Tanaka |
University of Tokyo Graduate School of Medicine
Opthalmology
113-8655
7-3-1 Hongo, Bunkyo-ku Tokyo 113-8655, Japan
03-3815-5411
rtanaka-ymn@umin.ac.jp
1st name | Keitaro |
Middle name | |
Last name | Hase |
Hokkaido University Graduate School of Medicine
Department of Opthalmology
060-8648
Kita-15,Nishi-7,Kita-ku,Sapporo 060-8648,Japan
011-706-5944
k.hase59@med.hokudai.ac.jp
University of Tokyo Graduate School of Medicine
University of Tokyo Graduate School of Medicine
Self funding
The Research Ethics Committee of the Graduate School of Medicine and Faculty of Medicine at The University of Tokyo
7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033 JAPAN
03-5841-0818
ethics@m.u-tokyo.ac.jp
NO
東京大学医学部附属病院
2015 | Year | 04 | Month | 10 | Day |
Unpublished
Completed
2014 | Year | 03 | Month | 31 | Day |
2014 | Year | 10 | Month | 16 | Day |
2014 | Year | 04 | Month | 01 | Day |
2023 | Year | 12 | Month | 31 | Day |
2015 | Year | 04 | Month | 09 | Day |
2020 | Year | 04 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019823